February 25, 2020
A New Jersey federal judge on Tuesday tossed Fresenius Kabi's antitrust suit against Par Pharmaceuticals, which alleged that the drug ingredient maker blocked it from marketing a generic version of an antidiuretic drug.
July 15, 2019
Par Pharmaceuticals and Fresenius both want a New Jersey federal judge to hand them wins in a lawsuit accusing Par of using its monopoly on an antidiuretic drug to raise prices and keep others out of the market.
February 10, 2017
A New Jersey federal court on Friday refused to throw out Fresenius' antitrust suit accusing Par Pharmaceutical Cos. of abusing its monopoly on an antidiuretic drug by raising prices and blocking others from entering the market, finding that Fresenius had adequately supported its claims.
July 28, 2016
Fresenius Kabi USA LLC on Wednesday filed suit in a New Jersey federal court against Par Pharmaceutical Cos. Inc., the maker of an intravenous vasopressin solution, alleging the company abused its monopoly position and hampered potential competitors from entering the market for the drug.